{
    "Project Title": "Phase II study evaluating combination chemotherapy + Radiotherapy (RT) with avelumab in muscle invasive bladder cancer.",
    "Sponsor": "Mayo Clinic Cancer Center",
    "Study Number": "MC1752",
    "Protocol Version and Date": "21JUN2018",
    "Study Title": "Phase II study evaluating combination chemotherapy + Radiotherapy (RT) with avelumab in muscle invasive bladder cancer.",
    "Phase": "Phase II",
    "Therapeutic Area": "Muscle Invasive Bladder Cancer",
    "Number of Patients": "Approximately 30 patients total",
    "Number of Sites": "Not Available",
    "Indication": "Muscle invasive bladder cancer (T2-T4a N0M0)",
    "Duration of Treatment": "10 cycles of Avelumab administered every 14 days",
    "Schedule of Assessments": "Section 4.0 and Table 2a",
    "questionnaires": [
        {
            "longName": "EORTC QLQ-BLM30",
            "shortName": "QLQ-BLM30",
            "type": "PRO",
            "questionnaireSchedule": "Baseline, end of treatment, 6 months follow-up, 9 months follow-up, 12 months follow-up",
            "questionnaireTiming": [
                "Tests and procedures: Screening (<28 days prior to reg)"
            ]
        },
        {
            "longName": "ECOG Performance Status",
            "shortName": "ECOG PS",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, every cycle and follow-up visits (up to 12 months)",
            "questionnaireTiming": [
                "Tests and procedures: Screening (\u226428 days prior to reg)",
                "Tests and procedures: C1 (D1)   (Active Monitoring Phase  )",
                "Tests and procedures: \u226470 days prior to reg"
            ]
        },
        {
            "longName": "Quality of Life (QOL) forms",
            "shortName": "QOL",
            "type": "PRO",
            "questionnaireSchedule": "Screening, every cycle and follow-up visits (up to 12 months)",
            "questionnaireTiming": [
                "Tests and procedures: Screening (\u226428 days prior to reg)"
            ]
        },
        {
            "longName": "Adverse Event Assessment",
            "shortName": "AE Assessment",
            "type": "ClinRO",
            "questionnaireSchedule": "Every visit during active monitoring phase",
            "questionnaireTiming": [
                "Tests and procedures",
                "Tests and procedures: Screening (\u226428 days prior to reg)",
                "Tests and procedures: C1 (D1)   (Active Monitoring Phase  )"
            ]
        }
    ]
}